Cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz plus P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D): Analysis by age group

被引：0
|
作者：
Malik, Zafar
di Lorenzo, Giuseppe
Bracarda, Sergio
Ardavanis, Alexandros
Basaran, Mert
Parente, Phillip
de Schultz, Wito
Saad, Fred
van Oort, Inge
Gerritsen, Winald R.
Aparicio, Luis M. Anton
Matus, Geoffrey
Hitier, Simon
Heidenreich, Axel
Bahl, Amit
机构：
[1] Clatterbridge Canc Ctr, Bebington, England
[2] Univ Naples Federico II, GU Canc Sect, Naples, Italy
[3] Ist Toscano Tumori ITT, Osped San Donato USL8, Arezzo, Italy
[4] St Savas Anticanc Hosp, Athens, Greece
[5] Istanbul Univ, Inst Oncol, Istanbul, Turkey
[6] Monash Univ, Box Hill Hosp, Eastern Hlth Clin Sch, Melbourne, Vic 3004, Australia
[7] Asklepios Klin, Urol Klin, Weissenfels, Germany
[8] Univ Montreal, Ctr Hosp, CRCHUM, Montreal, PQ, Canada
[9] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands
[10] Hosp Juan Canalejo, Dept Oncol, La Coruna, Spain
[11] Ctr Hosp Chretien Liege, Clin St Joseph, Liege, Belgium
[12] Sanofi, Chilly Mazarin, France
[13] Univ Hosp Aachen, Aachen, Germany
[14] Univ Hosp Bristol NHS Fdn Trust, Bristol Haematol & Oncol Ctr, Bristol, Avon, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.109
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
109
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Real-world evidence (RWE) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ): Comparison with the randomized clinical study CARD
    de Wit, R.
    Freedland, S.
    Oudard, S.
    Marinov, G.
    Capart, P.
    Combest, A.
    Peterson, R.
    Ozatilgan, A.
    Morgans, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S518 - S518
  • [22] Health-related quality of life (HRQL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ) in a prospective observational study (CAPRISTANA)
    Pichler, A.
    Barnes, G.
    Katolicka, J.
    Korunkova, H.
    Tomova, A.
    Ghosn, M.
    El Karak, F.
    Koroleva, I.
    Makdessi, J.
    Ozatilgan, A.
    Hitier, S.
    Carles, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [23] Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Huang, X.
    Ning, Y. M.
    Mulquin, M.
    Madan, R. A.
    Gulley, J. L.
    Kluetz, P. G.
    Adelberg, D.
    Arlen, P. M.
    Parnes, H. L.
    Adesunloye, B.
    Steinberg, S. M.
    Wright, J. J.
    Trepel, J. B.
    Chen, C.
    Bassim, C.
    Apolo, A. B.
    Figg, W. D.
    Dahut, W. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts)with metastatic castration-resistant prostate cancer (mCRPC)
    Huang, X.
    Ning, Y. M.
    Gulley, J. L.
    Kluetz, P. G.
    Adelberg, D.
    Mulquin, M.
    Madan, R. A.
    Bassim, C.
    Figg, W. D.
    Dahut, W. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [25] A phase I/II study of cabazitaxel (Cbz) combined with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed after docetaxel (D) chemotherapy: Preliminary results.
    Massard, Christophe
    Pezaro, Carmel
    Bobilev, Dmitri
    Omlin, Aurelius Gabriel
    Bianchini, Diletta
    Estelles, David Lorente
    Albiges, Laurence
    Loriot, Yohann
    Varga, Andrea
    Thi Xuan Quyen Nguyen
    Fizazi, Karim
    De Bono, Johann Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial.
    Sartor, A. O.
    Oudard, S.
    Ozguroglu, M.
    Hansen, S.
    Machiels, J. H.
    Shen, L.
    De Bono, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC)
    De Bono, J. S.
    Oudard, S.
    Ozguroglu, M.
    Hansen, S.
    Machiels, J. H.
    Shen, L.
    Matthews, P.
    Sartor, A. O.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] Safety results of the enzalutamide expanded access program in the United States and Canada for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.
    Joshua, Anthony M.
    Shore, Neal D.
    Saad, Fred
    Chi, Kim N.
    Olsson, Carl A.
    Emmenegger, Urban
    Scholz, Mark C.
    Berry, William R.
    Mukherjee, Som
    Winquist, Eric
    Haas, Naomi B.
    Hasabou, Nahla
    Dmuchowski, Carl
    Perabo, Frank
    Hirmand, Mohammad
    Foley, Margaret A.
    Rathkopf, Dana E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] Evaluation of continuous abiraterone acetate (AA) plus prednisone (P) dosing in fasting and fed states in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Chi, K. N.
    Spratlin, J.
    Kollmannsberger, C.
    North, S.
    Pankras, C.
    Chien, C.
    Gonzalez, M.
    Pang, L.
    Yu, M. K.
    Tran, N. P.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S696 - S697
  • [30] Phase I trial of apalutamide (Apa) with abiraterone acetate (AA) plus prednisone (P) and docetaxel (Doce) in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Nauseef, Jones T.
    Christos, Paul J.
    Thomas, Charlene
    Nordquist, Luke T.
    Sternberg, Cora N.
    Beltran, Himisha
    Guervil, Sabrina
    Galletti, Giuseppe
    Giannakakou, Paraskevi
    Nanus, David M.
    Tagawa, Scott T.
    Molina, Ana M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
12345